Position in NUVB
as of Jun 30, 2026
· filed Aug 7, 2026
Position Value
$156,943,148
+$49,262,551 QoQ
Shares Held
27,630,837
+10.1% QoQ
Ownership
7.87%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#2
of 242 holders
Holding Since
Sep 2024
8 quarters on record
Voting authority
Sole 96%
Shared 0%
None 4%
Common Shares in NUVB Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026BlackRock, Inc. holds $85,603,777,939 across 474 Biotechnology names. NUVB ranks #97 (0.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
24,109,373 | $11,975,848,839 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
9,113,506 | $5,682,635,520 | |
| 3 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
10,907,675 | $3,283,537,392 | |
| 4 | RVMD |
Revolution Medicines, Inc.
|
13,695,790 | $2,564,947,540 | |
| 5 | MRNA |
Moderna, Inc.
|
30,599,409 | $2,142,876,602 | |
| 6 | INCY |
Incyte Corp
|
18,032,718 | $2,044,188,902 | |
| 7 | CYTK |
Cytokinetics Inc
|
20,094,362 | $1,711,838,691 | |
| 8 | ROIV |
Roivant Sciences Ltd.
|
48,236,091 | $1,707,075,250 |
All Filings in NUVB
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $156,943,148 | 27,630,837 | Shares | Sole | 2026-08-07 | |
| 2026-03-31 | $107,680,597 | 25,100,374 | Shares | Sole | 2026-05-13 | |
| 2025-12-31 | $221,041,184 | 24,669,776 | Shares | Sole | 2026-02-12 | |
| 2025-09-30 | $91,035,383 | 24,604,159 | Shares | Sole | 2025-11-12 | |
| 2025-06-30 | $50,179,324 | 25,732,990 | Shares | Sole | 2025-08-12 | |
| 2025-03-31 | $32,522,660 | 18,478,787 | Shares | Sole | 2025-05-02 | |
| 2024-12-31 | $49,321,128 | 18,541,780 | Shares | Sole | 2025-02-07 | |
| 2024-09-30 | $38,870,447 | 16,973,997 | Shares | Sole | 2024-11-13 | |
| No filing history on record for this holder in this stock. | ||||||